COFEPRIS Generics Approval: What You Need to Know About the New Streamlined Process
Learn how COFEPRIS's updated generics approval process simplifies access to vital medications, enhancing availability for patients in need.
Quick Answer
Learn how COFEPRIS's updated generics approval process simplifies access to vital medications, enhancing availability for patients in need.
Key Questions
- What is the COFEPRIS abbreviated regulatory pathway?
- How fast are approvals under the new COFEPRIS pathway?
- Which regulatory agencies does COFEPRIS recognize?
- What documents are required for the abbreviated pathway?
Mexico's Federal Commission for Protection against Sanitary Risks (COFEPRIS) launched an abbreviated regulatory pathway on July 18, 2025, that recognizes prior approvals from the FDA, EMA, and other ICH member agencies to cut generic drug review times to 30 days—accelerating patient access to affordable medicines in Latin America's second-largest pharmaceutical market.
Contents9 sections
Key Takeaways
- 30-day timeline: COFEPRIS commits to resolving abbreviated pathway applications within 30 calendar days of receiving complete documentation, per the Diario Oficial de la Federación agreement.
- Reference agency recognition: The pathway recognizes approvals from the FDA, EMA, Health Canada, and other ICH member agencies.
- Market impact: Mexico's generic pharmaceutical market generated revenue exceeding USD 1.8 billion in 2025, with projections showing continued double-digit growth through 2033, according to pharmaceutical market analysis.
- ICH alignment: COFEPRIS is a regulatory member of the International Council for Harmonisation (ICH), enabling streamlined reliance on ICH member evaluations.
- Documentation requirements: Applicants must demonstrate equivalence through technical-scientific documentation rather than duplicating full reviews.
What Is the COFEPRIS Abbreviated Pathway?
The Federal Commission for Protection against Sanitary Risks (COFEPRIS) introduced an abbreviated regulatory pathway through an agreement published in Mexico's Diario Oficial de la Federación on July 18, 2025. This pathway allows COFEPRIS to recognize decisions, tests, and evaluation procedures from reference regulatory authorities (ARRs) and the World Health Organization's prequalification program as equivalent to Mexican requirements.
Generic drug manufacturers can now seek approval by demonstrating that their product is identical in quality, safety, and efficacy to a reference product already approved by a recognized agency. COFEPRIS adopts WHO Good Reliance Practices to avoid duplication of regulatory effort while maintaining stringent standards for patient safety.
Which Agencies Does COFEPRIS Recognize?
COFEPRIS recognizes regulatory authorities that are members of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and those participating in the WHO Prequalification Programme. The recognized agencies include:
| Agency | Region | Status |
|---|---|---|
| U.S. Food and Drug Administration (FDA) | United States | ICH Member |
| European Medicines Agency (EMA) | European Union | ICH Member |
| Health Canada | Canada | ICH Member |
| Swissmedic | Switzerland | ICH Member |
| Pharmaceuticals and Medical Devices Agency (PMDA) | Japan | ICH Member |
| Therapeutic Goods Administration (TGA) | Australia | ICH Member |
| WHO Prequalification Programme | International | Reference Standard |
Applicants must submit evidence that their product meets the same standards as those approved by these reference agencies. This recognition framework aligns Mexico with global regulatory harmonization efforts and reduces redundant testing requirements.
How Does the 30-Day Timeline Work?
The abbreviated pathway establishes a maximum 30-calendar-day review period from the date COFEPRIS receives complete technical-scientific documentation. This represents a significant acceleration compared to traditional generic drug approval timelines, which previously extended over several months.
The shortened timeline applies specifically to applications that demonstrate equivalence with products approved by reference regulatory authorities. COFEPRIS focuses its review on verifying the completeness and accuracy of submitted documentation rather than conducting duplicative evaluations already performed by recognized agencies.
Manufacturers must prepare comprehensive dossiers including bioequivalence studies, quality control data, manufacturing information, and evidence of the reference product's approval status. Incomplete applications may face delays or rejection.
What Is the Market Impact in Mexico?
Mexico represents the fastest-growing regional market for generic pharmaceuticals in North America. The market generated approximately USD 1.8 billion in revenue in 2025 and is projected to expand at a compound annual growth rate of 11.7%, reaching USD 4.6 billion by 2033.
Simple generics dominated the market in 2025, accounting for 77.3% of total revenue. Government procurement policies favoring affordable medicines, combined with an aging population and increasing chronic disease prevalence, continue driving demand for cost-effective generic alternatives.
The abbreviated pathway positions Mexico to attract increased generic drug investment by reducing regulatory barriers while maintaining quality standards. This could accelerate the entry of essential medicines for diabetes, cardiovascular disease, and other high-burden conditions.
What Should Manufacturers Prepare?
Pharmaceutical companies seeking to utilize the abbreviated pathway should ensure their documentation packages include several key components. First, evidence of the reference product's approval by a recognized regulatory authority is essential. Second, comprehensive bioequivalence studies demonstrating pharmaceutical equivalence must meet international standards.
Quality documentation should cover active pharmaceutical ingredient characterization, manufacturing process validation, stability data, and analytical methods. Companies should also prepare administrative documents including certificates of pharmaceutical product (CPP) from reference agencies where available.
Working with regulatory consultants familiar with both Mexican requirements and reference agency standards can streamline preparation. Early engagement with COFEPRIS through pre-submission meetings may help identify potential documentation gaps before formal filing.
Frequently Asked Questions
What is the COFEPRIS abbreviated regulatory pathway?
The COFEPRIS abbreviated regulatory pathway is a streamlined approval process implemented on July 18, 2025, that recognizes prior authorizations from reference regulatory agencies like the FDA and EMA to expedite generic drug approvals in Mexico.
How fast are approvals under the new COFEPRIS pathway?
COFEPRIS commits to resolving abbreviated pathway applications within 30 calendar days of receiving complete technical-scientific documentation demonstrating equivalence with recognized reference standards.
Which regulatory agencies does COFEPRIS recognize?
COFEPRIS recognizes the FDA, EMA, Health Canada, Swissmedic, Japan's PMDA, Australia's TGA, and the WHO Prequalification Programme as reference regulatory authorities under the abbreviated pathway.
What documents are required for the abbreviated pathway?
Applicants must submit technical-scientific documentation demonstrating that their product is equivalent to one already approved by a recognized reference regulatory agency, including bioequivalence studies and quality data.
Primary Sources
- Diario Oficial de la Federación — Official agreement establishing the abbreviated regulatory pathway, published July 18, 2025.
- International Council for Harmonisation (ICH) — Member organizations including COFEPRIS, FDA, EMA, and other reference regulatory authorities.
- U.S. Food and Drug Administration — Reference regulatory agency for generic drug approvals recognized by COFEPRIS.
- European Medicines Agency — Reference regulatory agency for generic drug approvals recognized by COFEPRIS.
- World Health Organization Prequalification Programme — Technical standards and good reliance practices referenced in COFEPRIS equivalence determinations.
Related Coverage
This article follows our editorial standards. Report a correction via editorial contact.
